Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (764)	11/14/2005 5:21:36 PM
From: Icebrg	Respond to of 946

>>Textbook case of what bad fiscal responsibility can do to s/h value.>> I would say it is more a textbook case of extremely poor clinical planning. They were running three very large, expensive, poorly planned phase III trials for a product that had not yet - as far as I know - been taken through a single randomized blinded trial for the indication in question. Very few companies of CTIC's limited size would have been able to come through that, without having its capital structure destroyed. Erik